Youcare Pharmaceutical (SH:688658)2021-04-28 16:00Financial Performance - Operating revenue for the reporting period was CNY 879,074,205.93, an increase of 19.22% year-on-year[11] - Net profit attributable to shareholders was CNY 70,192,335.25, representing a significant increase of 93.51% compared to the same period last year[11] - Basic earnings per share increased by 60.00% to CNY 0.16[11] - Total operating revenue for Q1 2021 reached ¥879,074,205.93, an increase of 19.2% compared to ¥737,328,516.12 in Q1 2020[52] - Net profit for Q1 2021 was ¥70,276,993.94, compared to ¥36,108,507.54 in Q1 2020, representing an increase of 94.5%[52] - The company's operating revenue for Q1 2021 reached ¥658,134,194.91, a 34.3% increase from ¥490,357,040.12 in Q1 2020[54] - Net profit for Q1 2021 was ¥40,622,404.16, compared to ¥15,500,178.11 in Q1 2020, representing a 161.3% increase[58] - Total comprehensive income for Q1 2021 was ¥40,622,404.16, compared to ¥15,500,178.11 in Q1 2020, indicating a significant growth[58] Cash Flow - The net cash flow from operating activities was negative at CNY -7,797,646.28, a decrease of 114.98% compared to the previous year[11] - The net cash flow from operating activities decreased by 114.98% to -¥7,797,646.28, primarily due to increased marketing and advertising expenses[28] - The company reported a net cash flow from operating activities of -¥7,797,646.28 in Q1 2021, a decrease from ¥52,057,480.29 in Q1 2020[62] - The cash inflow from operating activities totaled ¥1,097,135,969.96 in Q1 2021, up from ¥876,750,946.90 in Q1 2020[62] - The cash outflow from operating activities was ¥785,095,020.96, up from ¥643,930,539.23 in Q1 2020, reflecting an increase of approximately 21.9%[64] - The company reported a net cash flow from investing activities of -¥339,333,670.64 in Q1 2021, compared to ¥17,730,305.52 in Q1 2020, indicating a significant increase in cash outflow[66] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,216,886,446.80, a decrease of 4.40% compared to the end of the previous year[11] - Total liabilities decreased from 1,871,102,363.29 to 1,560,714,944.57, a decline of about 16.6%[40] - Current liabilities decreased from 1,779,168,640.95 to 1,444,797,770.51, a reduction of about 18.8%[39] - Cash and cash equivalents decreased from 2,337,846,231.61 to 2,026,831,331.24, a decrease of approximately 13.3%[42] - Accounts receivable decreased from 476,083,914.84 to 319,842,082.93, a decline of around 32.8%[42] - Total liabilities amounted to ¥1,871,102,363.29, with current liabilities totaling ¥1,779,168,640.95[72] - The total assets of the company as of the end of Q1 2021 amounted to ¥5,456,996,871.58, a slight decrease from ¥5,472,888,736.84 at the end of the previous year[68] Shareholder Information - The total number of shareholders at the end of the reporting period was 30,826[16] - The largest shareholder, Fuyang Jingyue Yongshun Information Consulting Co., Ltd., held 40.05% of the shares[16] - Shareholders' equity increased from 3,585,894,508.29 to 3,656,171,502.23, an increase of approximately 2.0%[40] - Total equity attributable to shareholders reached ¥3,580,924,323.01, while total equity was ¥3,585,894,508.29[74] Expenses - Research and development expenses accounted for 4.17% of operating revenue, an increase of 0.38 percentage points year-on-year[11] - The company’s sales expenses rose by 40.95% to ¥391,028,556.61, attributed to increased product marketing efforts[28] - Total operating costs for Q1 2021 were ¥800,319,681.90, up from ¥695,352,587.41 in Q1 2020, reflecting a rise of 15.1%[52] - Research and development expenses for Q1 2021 amounted to ¥32,487,090.30, an increase from ¥23,807,981.81 in Q1 2020, showing a growth of 36.5%[52] - The company’s financial expenses decreased significantly by 216.26% to -¥6,010,780.12, due to loan repayments and increased interest income from raised funds[28] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[67]